CD32B1,一种多功能非信号抗体结合支架,用于增强T细胞对瘤 stromal 相关抗原的附着性
Sara W Feigelson1, Tali Dadosh2, Nehora Levi1
1Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.
Frontiers in immunology
|February 25, 2025
概括
研究人员开发了一种新的方法,通过用抗体装饰T细胞来增强固体瘤的T细胞治疗. 这一策略改善了T细胞在瘤中的粘附和保留,为癌症治疗提供了一种有前途的方法.
科学领域:
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
- 在瘤学瘤学.
背景情况:
- 用T细胞 (CAR-T,TCR-T,TILs) 准固体瘤在实现有效瘤透和保留方面面临挑战.
- 目前的T细胞疗法难以克服瘤微环境中的物理和生物障碍.
研究的目的:
- 开发一种新的策略来增强T细胞 (淋巴细胞) 在固体瘤中的粘附和保留.
- 为了设计T细胞,使其对瘤特异性表面蛋白具有新的粘附性.
主要方法:
- 具有非信号Fc受体支架 (ITIM-less CD32B1) 的工程T细胞可以结合单克隆抗体 (mAbs).
- 开发了一种融合蛋白 (mSA2-CD8h-tILCD32B1) 用于生物化mAb结合,增强T细胞的粘合性.
- 测试了mAb装饰的T细胞与同类抗原结合,并在小鼠乳腺瘤中保持.
主要成果:
- 工程T细胞成功与IgG1mAbs结合,并表现出对表面结合抗原的增强粘附性.
- mSA2-CD8h-tILCD32B1支架促进了生物化mAbs与T细胞的稳定结合.
- 用生物化mAbs装饰的T细胞在体内显示乳腺瘤中的长时间保留.
结论:
- 非信号的CD32B1作为T细胞抗体装饰的多功能支架.
- 这种抗体装饰方法可以改善固体瘤中T细胞的积累和保留.
- 该战略有可能增强像CAR-T和TILs这样的采用性T细胞疗法,用于固体瘤.
相关概念视频
T Cell Activation and Clonal Selection
627
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
627
Immunoglobulin-like Cell Adhesion Molecules
3.2K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.2K
Tumor Immunotherapy
463
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
463


